Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.
about
Influence of diabetes mellitus on heart failure risk and outcomeDiet and hemostatic factors.Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjectsPlasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia.Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.PAI-1 and diabetes: a journey from the bench to the bedside.Pathobiology and cell interactions of platelets in diabetes.Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanismsRelevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1.Systems pharmacology of adverse event mitigation by drug combinationsA Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription.Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription.Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis.The status of plasminogen activator inhibitor-1 as a therapeutic target.Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patientsReciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.Regulation of PAI-1 gene expression during adipogenesis.Intact insulin, insulin propeptides, and intima-media thickness in the femoral artery in 58-year-old clinical healthy men--the Atherosclerosis and Insulin Resistance Study.Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome?Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up.Metabolic effects of long-term growth hormone treatment in prepubertal children with chronic renal failure and after kidney transplantation. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure.Serum soluble adhesion molecule concentrations are not regulated by acute hyperinsulinaemia in healthy men.Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants.The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study
P2860
Q24800363-018CDCA8-1A47-4503-AC0A-CC9FEA6BB101Q34107288-F36EA5C5-5D1C-4719-B614-833569E7F0D6Q34452976-298F5589-DE2E-40A5-8861-C0A8B29FE9A4Q34722566-11DEDDAE-4375-4A77-82E3-616492EDBD56Q35181647-67C1F1D9-47D5-40C7-A09D-899A80985343Q35567290-8E393366-0CE0-4DC2-B78A-4295AC2EE165Q35721055-0E9C516A-EE1D-4C66-B96F-F803D1EBE6E4Q35847886-E32626EB-60E4-4A62-9DAE-6AB000A0AC73Q36249561-696F0BC5-FE54-4D5D-B3C1-17F272730628Q36320564-D97B9F79-A3E5-4989-AEAA-2EA9A0569FF6Q36415843-48B00E72-7E38-43CB-99FF-B96804E1D28BQ36437973-F6474AB6-DBE9-482F-81B7-171BC9FBCDB1Q37172857-CA7ECE81-9935-4423-9403-40508ED4652AQ37207656-AA2161A4-6896-4224-8CB3-D8CED5EA8D74Q37369762-AA68381D-6CAC-4389-B84A-52731C76B58BQ37658567-37BA5835-9052-484A-B99A-B966871180CDQ38290766-321320DC-1466-4CAD-A9DB-77203372DA8EQ38342702-FEBDA50E-5408-4CA4-A954-49FF7B1DE37FQ39315148-E0E048F8-2AC9-4F1F-A2A8-8F7D5CC59C6DQ40894566-A009BC14-8AF3-43FB-B74D-0A8993CED817Q41156168-2B71CE10-8D02-4176-AA02-DACF5932D242Q41534557-EEA71AD3-0C87-417A-8D08-1F5A012D8AD7Q42554965-A37AD907-A5F5-4F02-97D2-D7C2E7678801Q42825179-F9AE70FE-2EAF-4803-8C80-79100A02310CQ42831962-5DE68114-149B-47B0-B976-D32B421CA4AAQ43593322-32CF0D3F-79BA-4808-BC3E-411DCB9C633AQ43865647-AC29691A-1B44-48FB-B500-F1ECB1818C45Q46916782-544479D0-221A-4334-82BB-D77262F23794Q46979381-AF112F8A-99D4-4789-AFA6-D6E33969998EQ50628603-C6BBC9C5-244D-4FFB-89F9-8A8F44F7509CQ51561718-B9CC0F7B-3F63-4E31-B21B-EC882350F064Q53568084-AF32A20C-47CC-4F4F-A558-5F78783879ADQ57398894-DC33375A-7DAD-4FBA-A019-118202754E7C
P2860
Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Induction of plasminogen activ ...... roinsulin and insulin in vivo.
@en
Induction of plasminogen activator inhibitor type-1
@nl
type
label
Induction of plasminogen activ ...... roinsulin and insulin in vivo.
@en
Induction of plasminogen activator inhibitor type-1
@nl
prefLabel
Induction of plasminogen activ ...... roinsulin and insulin in vivo.
@en
Induction of plasminogen activator inhibitor type-1
@nl
P2093
P356
P1433
P1476
Induction of plasminogen activ ...... roinsulin and insulin in vivo.
@en
P2093
P304
P356
10.1161/01.CIR.91.3.764
P407
P577
1995-02-01T00:00:00Z